|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2B
|
|
pubmed:dateCreated |
2000-5-31
|
|
pubmed:abstractText |
Tumor stage and nodal status are the most important factors predicting locoregional recurrence in breast cancer. We wanted to investigate the prognostic value of some newer molecular genetic markers for the occurrence of a locoregional recurrence, in order to improve the selection of patients for locoregional adjuvant therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD44,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Nuclear,
http://linkedlifedata.com/resource/pubmed/chemical/CD44v6 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Genetic Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Medroxyprogesterone Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/TFF1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1269-75
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:10810433-Adult,
pubmed-meshheading:10810433-Aged,
pubmed-meshheading:10810433-Antigens, CD44,
pubmed-meshheading:10810433-Antigens, Nuclear,
pubmed-meshheading:10810433-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10810433-Apoptosis,
pubmed-meshheading:10810433-Breast Neoplasms,
pubmed-meshheading:10810433-Chemotherapy, Adjuvant,
pubmed-meshheading:10810433-Combined Modality Therapy,
pubmed-meshheading:10810433-Disease-Free Survival,
pubmed-meshheading:10810433-Female,
pubmed-meshheading:10810433-Genetic Markers,
pubmed-meshheading:10810433-Glycoproteins,
pubmed-meshheading:10810433-Humans,
pubmed-meshheading:10810433-Ki-67 Antigen,
pubmed-meshheading:10810433-Mastectomy, Modified Radical,
pubmed-meshheading:10810433-Medroxyprogesterone Acetate,
pubmed-meshheading:10810433-Middle Aged,
pubmed-meshheading:10810433-Neoplasm Recurrence, Local,
pubmed-meshheading:10810433-Nuclear Proteins,
pubmed-meshheading:10810433-Phenotype,
pubmed-meshheading:10810433-Ploidies,
pubmed-meshheading:10810433-Proteins,
pubmed-meshheading:10810433-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10810433-S Phase,
pubmed-meshheading:10810433-Tumor Suppressor Protein p53,
pubmed-meshheading:10810433-Tumor Suppressor Proteins
|
|
pubmed:articleTitle |
Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer.
|
|
pubmed:affiliation |
Radiotherapeutisch Instituut Limburg, Heerlen, Maastricht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
